Prenetics Global Limited (NASDAQ:PRE - Get Free Report) fell 1.6% during mid-day trading on Friday . The stock traded as low as $5.70 and last traded at $5.70. 1,032 shares changed hands during mid-day trading, a decline of 98% from the average session volume of 48,158 shares. The stock had previously closed at $5.79.
Wall Street Analyst Weigh In
Separately, Cantor Fitzgerald reissued an "overweight" rating and set a $9.00 target price on shares of Prenetics Global in a research note on Wednesday, December 4th.
Read Our Latest Analysis on PRE
Prenetics Global Price Performance
The stock's 50 day moving average is $4.88 and its two-hundred day moving average is $5.12. The stock has a market capitalization of $52.08 million, a PE ratio of -1.43 and a beta of -0.18.
Prenetics Global (NASDAQ:PRE - Get Free Report) last announced its quarterly earnings data on Monday, October 7th. The company reported ($0.88) EPS for the quarter. The firm had revenue of $5.94 million during the quarter. Prenetics Global had a negative net margin of 191.73% and a negative return on equity of 16.45%. On average, equities analysts predict that Prenetics Global Limited will post -3.3 earnings per share for the current year.
Prenetics Global Company Profile
(
Get Free Report)
Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.
See Also
Before you consider Prenetics Global, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prenetics Global wasn't on the list.
While Prenetics Global currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
